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Epstein–Barr virus-encoded microRNA BART1
induces tumour metastasis by regulating
PTEN-dependent pathways in nasopharyngeal
carcinoma
Longmei Cai1,*, Yanfen Ye1,2,*, Qiang Jiang1,*, Yuxiang Chen1,*, Xiaoming Lyu1,*, Jinbang Li1, Shuang Wang3,
Tengfei Liu3, Hongbing Cai4, Kaitai Yao1, Ji-Liang Li5,6,** & Xin Li1,**
Epstein–Barr virus (EBV), aetiologically linked to nasopharyngeal carcinoma (NPC), is the ﬁrst
human virus found to encode many miRNAs. However, how these viral miRNAs precisely
regulate the tumour metastasis in NPC remains obscure. Here we report that EBV-miR-BART1
is highly expressed in NPC and closely associated with pathological and advanced clinical
stages of NPC. Alteration of EBV-miR-BART1 expression results in an increase in migration
and invasion of NPC cells in vitro and causes tumour metastasis in vivo. Mechanistically,
EBV-miR-BART1 directly targets the cellular tumour suppressor PTEN. Reduction of PTEN
dosage by EBV-miR-BART1 activates PTEN-dependent pathways including PI3K-Akt,
FAK-p130Cas and Shc-MAPK/ERK1/2 signalling, drives EMT, and consequently increases
migration, invasion and metastasis of NPC cells. Reconstitution of PTEN rescues all pheno-
types generated by EBV-miR-BART1, highlighting the role of PTEN in EBV-miR-BART-driven
metastasis in NPC. Our ﬁndings provide new insights into the metastasis of NPC regulated by
EBV and advocate for developing clinical intervention strategies against NPC.
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N
asopharyngeal carcinoma (NPC) represents a serious
health problem in Southern China and Southeast Asia
and has a high metastatic potential. Most patients with
the disease are diagnosed only when the tumour has reached
an advanced stage (stages III and IV)1. Interactions among
environmental carcinogens, genetic alternations and viral
infections are believed to play a major role in the pathogenesis
of NPC2. However, the molecular mechanisms for the metastases
of NPC remain obscure.
The Epstein–Barr virus (EBV), latently infected 490% of the
global population, is aetiologically linked to several human
lymphocytic and epithelial malignancies including Burkitt’s
lymphoma, Hodgkin’s disease, post-transplant lymphoma, gastric
cancer (GC) and NPC3. To date, most studies have focused on
EBV-encoded proteins such as the latent nuclear antigen EBNA1
(ref. 4) and the latent membrane proteins LMP1, LMP2A and
LMP2B, which have the abilities to transform cells, to alter
cellular gene expression and to increase the growth, survival and
invasion of transformed cells4,5. However, EBV-associated
tumours usually express a restricted repertoire of viral proteins
in a histological speciﬁc fashion6, suggesting that the pathogenesis
and progression of these tumours are not only regulated by viral
proteins but also by other important factors such as EBV-encoded
microRNAs (EBV-miRs).
MicroRNAs (miRNAs), a class of 17–23 nucleotide non-coding
RNAs, are capable of inhibiting the expression of multiple target
genes by forming imperfect complementary duplexes with their
target mRNAs in the 30-untranslated region (30-UTR), leading to
mRNA degradation or translational inhibition7, and participate in
diverse biological processes including tumorigenesis and
metastasis8. EBV is the ﬁrst human virus found to encode
miRNAs9. To date, a total of 25 EBV-miR precursors containing
48 mature miRNAs have been identiﬁed within two regions of the
EBV genome. The BamHI fragment H rightward reading frame 1
(BHRF1) gene encodes 3 miRNA precursors (that is, EBV-miR-
BHRF1 1–3) generating four mature miRNAs, while the BamHI
fragment A rightward transcript (BART) region contains 22
miRNA precursors (that is, EBV-miR-BART1-22) producing 44
mature miRNAs10–12. The abundance of individual miRNAs
within cell lines and tumour tissues varies widely and appears to
be cell-type and tumour-type speciﬁc. The expression of EBV-
miR-BHRF1 was highly restricted to lytic and latency III-infected
cell lines such as B lymphoma cells, whereas EBV BART miRNAs
were detected in all types of EBV-associated latency10,13–21.
Interestingly, the expression of BART miRNAs was shown to be
relative low in EBV-infected B lymphocytes but extremely high in
infected epithelial tissues, suggesting a pathogenic role in the
development of epithelial malignancies15,17,21–23.
Many EBV BART miRNAs were found highly expressed in
NPC and GC22,24,25, contributing to viral latency23,26,27, host cell
survival25,27 and immune escape28. However, their functions in
tumorigenesis and tumour progression of NPC remain elusive.
We are interested in the viral and cellular miRNAs in the tumour
biology and clinical signiﬁcance in NPC29,30. In this study, we
report that EBV-miR-BART1 is highly expressed in NPC and
closely associated with pathoclinical features of NPC. Alterations
of the expression of EBV-miR-BART1 demonstrated that it
induces the migration and invasion of NPC cells in vitro and the
tumour metastasis in vivo. The underlying molecular mechanisms
by which BART1 causes tumour metastasis are revealed to
directly target the major tumour suppressor, phosphatase and
tensin homologue (PTEN) and consequently to activate
PTEN-dependent pathways and induce epithelial–mesenchymal
transition (EMT). Our ﬁndings provide new insights into the
metastasis of NPC regulated by EBV and advocate for developing
clinical intervention strategies for NPC.
Results
EBV-miR-BART1 is associated with pathoclinical features. We
performed miRNA expression proﬁle microarray analysis of
20 NPC versus 20 non-cancerous nasopharyngeal (NP) tissues
(Supplementary Table 1) and identiﬁed 69 miRNAs that were
differentially expressed between NPC and NP samples (Fig. 1a).
Of them, 24 miRNAs were upregulated and 45 miRNAs were
downregulated in NPC specimens. Intriguingly, among all
upregulated miRNAs, 62.5% (15/24) were EBV BART miRNAs,
while only 29.2% (7/24) were human cellular miRNAs
(Supplementary Table 2). In contrast, all downregulated miRNAs
were host derived, of which a large proportion (55.6%, 25/45)
were tumour suppressive miRNAs such as the let-7 family
(hsa-let-7c, d, g and i)31, miR-34 family (miR-34c and d)32,
miR-29 family (miR-29a, b and c)32, miR-30 family (miR-30a-5p,
30a-3p, b, d and e)33, miR-26 family (miR-26a and b)34,
miR-143/145 cluster35, miR-16 (ref. 36), miR-31 (ref. 37),
miR-101 (ref. 38), miR-146a39, miR-150 (ref. 40), miR-152
(ref. 41) and miR-195 (ref. 42). Notably, BART1, BART7, BART3,
BART10, BART8, BART9 and BART5 were in the top seven and
clustered together, suggesting that EBV BART miRNAs may play
a critical role in NPC.
To investigate if the EBV-miR-BART1 expression is associated
with pathoclinical features of NPC, we determined the expression
of EBV-miR-BART1 in another cohort of 82 NPC samples that
contain the TNM-stage information (Supplementary Table 3).
The expression of either BART1-5p (3.8-fold) or BART1-3p
(2.9-fold) was dramatically increased in N2–3 stages as compared
with N0–1 stages (Fig. 1b). Similarly, a substantial higher level of
BART1-5p (3.4-fold) or BART1-3p (3.0-fold) was observed in
advanced clinical stage III–IV than in early clinical stage I–II
(Fig. 1c). Thus, the results suggest that EBV-miR-BART1 might
contribute to the metastasis of NPC.
EBV-miR-BART1 impels NPC metastasis in vitro and in vivo.
We upregulated the expression of BART1 in two EBV-negative
NPC cell lines (CNE1 and 5-8F) by lentivirus-mediated
transduction (Supplementary Fig. 1). Transwell migration assays
(Fig. 2a) and wound-healing assays (Supplementary Fig 2)
demonstrated that upregulation of BART1 dramatically increased
the cell migration of either CNE1-BART1 or 5-8F-BART1 com-
pared with relative mock control. Boyden chamber invasion
assays (Fig. 2b) revealed that the upregulation of BART1
signiﬁcantly increased the cell invasion of both CNE1-BART1
and 5-8F-BART1 compared with the relative control. To verify
the results, we downregulated the expression of BART1 in CNE1-
BART1 and 5-8F-BART1 by transfection of BART1-inhibitory
oligonucleotides (Supplementary Fig. 3). Consistent with the
upregulation results, downregulation of BART1 by either
in-b1-5p or in-b1-3p dramatically decreased the migration
(Fig. 2c) and invasion (Fig. 2d) of either CNE1-BART1 or
5-8F-BART1 cells compared with the relative in-NC control.
An additive effect on cell migration or invasion was observed
when combined the two BART1 inhibitors (Fig. 2c,d). Together
these results suggest that EBV-miR-BART1 propels the migration
and invasion of NPC cells in vitro.
We xenografted 5-8F-BART1 cells into nude mice.
Upregulation of BART1 signiﬁcantly increased the tumour
growth of 5-8F-BART1 compared with the 5-8F-mock control
(Fig. 2e,f). Transplantation of 5-8F cells underneath the liver
envelope43,44 demonstrated that the upregulation of BART1
promoted the tumour metastasis of 5-8F-BART1 compared with
the 5-8F-mock control (Fig. 2g). Three weeks after the
transplantation, 86% of mice (6/7) in the 5-8F-BART1 group
showed both liver and lymph node metastases compared with
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14% of mice (1/7) in the 5-8F-mock group (Chi-square test
Po0.05); 43% of mice (3/7) in the 5-8F-BART1 group displayed
lung metastasis compared with 14% of mice (1/7) in the control
group (Fig. 2h). In the metastasized lymph nodes, 45 tumour
nodules in the 5-8F-BART1 tumours were observed compared
with ﬁve nodules in the control tumours (6.43±2.13 versus
0.71±0.71, Student’s t test Po0.05; see Fig. 2h). Re-examination
of EBV-miR-BART1 expression in liver-metastasized tumours by
quantitative reverse transcription PCR (qRT–PCR) demonstrated
that the metastasized tumour cells stably expressed BART1-5p
and BART1-3p at the levels close to that of NPC clinical samples
(Supplementary Fig. 4). Thus, the results indicate that EBV-miR-
BART1 impels the growth and metastasis of NPC cells in vivo.
EBV-miR-BART1 directly targets cellular PTEN in NPC cells.
We investigated BART1-targeted genes that are associated with
tumour metastasis by developing an integrated strategy (Fig. 3a).
RNA-deep sequencing analysis of the gene expression proﬁling of
CNE1-BART1 cells versus CNE1-mock cells identiﬁed 995
downregulated genes, from which many metastasis-associated
candidates can be retrieved (Supplementary Table 4 and
Supplementary Fig. 5). Pathway enrichment analysis for these
downregulated genes revealed that BART1 regulated many
important signalling pathways such as p53 signalling pathway,
pathway in cancer, MAPK pathway, regulation of actin
cytoskeleton, Jak-STAT signalling pathway and focal adhesion
pathway. At least 10 genes were signiﬁcantly altered in each of
these pathways by BART1. PTEN was identiﬁed as one of the
top genes regulated by BART1 and involved in ﬁve tumour
metastasis- or cell invasion-associated pathways.
Bioinformatics analysis showed that PTEN 30-UTR region
contains two sites complementary with the seed sequences of
BART1-5p and BART1-3p from the nucleotide position 425 and
921, respectively (Fig. 3b). To clarify if PTEN is a direct cellular
target for BART1, we performed luciferase reporter assays by
co-transfection of a wild-type (wt) or mutant (mut 1 or mut 2)
PTEN 30-UTR-containing luciferase reporter vector with a
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Figure 1 | EBV-miR-BART1 is highly expressed in NPC and associated with clinicopathological features. (a) MiRNA expression proﬁle microarray
screening. Supervised hierarchical cluster analysis of 69 miRNAs that were differentially expressed between 20 NPC and 20 NP biopsies (universal test
Po0.005, fold-change 41.5, false discovery rate o0.05). Left: heatmap of the 69 miRNAs differentially expressed between NPC and NP samples.
Red represents upregulated miRNAs and blue for downregulated miRNAs. Right-up: the top seven upregulated EBV BART miRNAs clustered together.
Right-down: a volcano plot for the visualization of differentially expressed miRNAs with signiﬁcance cut off Po0.005 and fold-changeZ1.5 symmetrically
in NPC compared with NP. The top 11 upregulated EBV BART miRNAs in NPC were highlighted by a red dot-line square. (b) EBV-miR-BART1 was highly
expressed in late pathological stages of NPC. The expression of EBV-miR-BART1 in a separated cohort of 82 NPC samples was determined by qRT–PCR.
RPU6B was used for normalizing the expression of BART1-5p or BART1-3p. Student’s t-test, mean±s.e.m., *Po0.05, **Po0.01. (c) EBV-miR-BART1 was
highly expressed in advanced clinical stages of NPC. Both BART1-5p and BART1-3p were highly expressed in advanced clinical stages (III–IV) compared
with that of early clinical stages (I–II). Student’s t-test, mean±s.e.m., *Po0.05, **Po0.01.
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Figure 3 | EBV-miR-BART1 targets tumour suppressor PTEN in NPC. (a) Development of the integrated strategy for discovering targeted genes of
EBV-miR-BART1. (b) Bioinformatics predictions of two binding sites by BART1-5p and BART1-3p in PTEN 30-UTR region. Wild-type (wt) and two mutant
sequences are indicated. (c) Luciferase reporter assays. HEK293Tcells were co-transfected with wt or mutated PTEN 30-UTR and the BART1 mimic (either
b1-5p for BART1-5p or b1-3p for BART1-3p) or nonspeciﬁc mimic control (NC). Relative repression of ﬁreﬂy luciferase expression was standardized to a
transfection control. One-way ANOVA and Dunnett’s multiple comparison test. (d) The expression of PTEN in two cell lines and tumour sections of 5-8F
xenografts and metastasized organs. Up panels are representatives of IF staining for PTEN (red) in both CNE1-BART1 and 5-8F-BART1 cells and relative
mock control cells. Nuclei were stained with DAPI (blue). Low panels are the representatives of IHC staining for PTEN in metastasized tumours (liver and
lymph node) from 5-8F tumours. Original magniﬁcation, 400; scale bar, top panel 10mm, bottom panel 25mm. (e) The expression of PTEN at mRNA
level in 32 NP and 82 NPC specimens determined by qRT–PCR. Left panel: signiﬁcant downregulation of PTEN in N2–3 pathological stages compared with
that of N0–1 stages or with NP. Right panel: signiﬁcant downregulation of PTEN in advanced clinical stages (III–IV) compared with early clinical stages (I–II)
or compared with NP. (f) Reverse correlation of the expression EBV-miR-BART1 and PTEN. Left: BART1-5p versus PTEN, right: BART1-3p versus PTEN. Two-
tailed Spearman’s correlation analysis. One-way ANOVA and Dunnett’s multiple comparison test. Mean±s.e.m., **Po0.01, ***Po0.001.
Figure 2 | EBV-miR-BART1 propels cell migration and invasion in vitro and tumour metastasis of NPC in vivo. (a) Transwell migration assays.
Upregulation of BART1 miRNA increased the cell migration of both CNE1-BART1 and 5-8F-BART1 compared with relative mock cells. Student’s t-test.
(b) Boyden chamber invasion assays. Upregulation of BART1 miRNA increased the cell invasion of both CNE1-BART1 and 5-8F-BART1 compared with
relative mock cells. Student’s t-test. (c) Downregulation of BART1 miRNA by the BART1 inhibitor decreased the cell migration of both CNE1-BART1 and
5-8F-BART1. One-way ANOVA and Dunnett’s multiple comparison test. (d) Downregulation of BART1 miRNA by the BART1 inhibitor decreased the cell
invasion of both CNE1-BART1 and 5-8F-BART1. One-way ANOVA and Dunnett’s multiple comparison test. (e) Xenograft tumours collected on day 21 post
subcutaneous implantation of 5-8F cells. Upregulation of BART1 increased the tumour growth in nude mice (5-8F-BART1 versus 5-8F-mock). (f) Tumour
growth curves. Upregulation of BART1 increased the tumour growth in nude mice (5-8F-BART1 versus 5-8F-mock). N¼ 7, parametric generalized linear
model with random effects. (g) Representative GFP images of tumour metastasis. Upregulation of BART1 increased the tumour metastasis in lung, liver and
lymph nodes. N¼ 7. (h) Upregulation of BART1 increased the tumour metastasis in lung, liver and lymph nodes. N¼ 7, w2-test for left panel and Student’s
t-test for right panel. Original magniﬁcation,  200; scale bar, 25 mm. Mean±s.e.m., N¼ 3, *Po0.05, **Po0.01, ***Po0.001.
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BART1 mimic. The luciferase activity of the wt PTEN 30-UTR but
not the mutant 30-UTR (either mut 1 or mut 2) was signiﬁcantly
reduced by b1-5p mimic alone or b1-3p mimic alone but not by
the control mimic (NC). The combination of b1-5p with b1-3p
produced an additive effect on the luciferase activity (Fig. 3c).
The effects of EBV-miR-BART1 on PTEN mRNA and protein
expression were examined in NPC cell lines, xenografted tumours
and clinical samples. Upregulation of BART1 signiﬁcantly
reduced the expression of PTEN in both CNE1-BART1 and
5-8F-BART1 cell lines compared with the relative control as
revealed by western blotting and immunoﬂuorescent (IF) staining
(Fig. 3d, upper panels). Immunohistochemical (IHC) staining on
tumour sections of xenografts and metastasized organs demon-
strated that the upregulation of BART1 signiﬁcantly reduced the
expression of PTEN in 5-8F-BART1 tumours compared with
the 5-8F-control tumours (Fig. 3d, lower panels). Detection of the
PTEN mRNA by qRT–PCR revealed that the expression of PTEN
in clinical tumour samples was signiﬁcantly decreased in N2–3
stages as compared with either N0–1 stages (0.1673±0.0295
versus 0.3927±0.0435, Po0.0001) or NP (0.1673±0.0295 versus
1.2100±0.1247, Po0.0001; Fig. 3e, left panel). Similarly,
the expression of PTEN was signiﬁcantly lower in advanced
clinical stages III–IV than in either early clinical stages I–II
(0.1683±0.0210 versus 0.4088±0.0331, Po0.0001) or NP
(0.1683±0.0210 versus 1.2100±0.1247, Po0.0001; Fig. 3e, right
panel). Strikingly, the expression of PTEN in NPC was highly
inversely correlated with the expression of either BART1-5p
(r¼  0.5205, Po0.0001; Fig. 3f, right panel) or BART1-3p
(r¼  0.3687, P¼ 0.0007; Fig. 3f, left panel). Taken together,
these data indicate that PTEN is a direct cellular target of
EBV-miR-BART1 in NPC.
EBV-miR-BART1 activates PTEN-dependent signalling pathways.
We examined the expression alterations of key components of
PTEN-dependent pathways in NPC. Western blotting showed
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Figure 4 | EBV-miR-BART1 activates PTEN-dependent pathways. (a) Upregulation of EBV-miR-BART1 decreased the protein expression of PTEN but
increased the expression of p-Akt, FAK, p-FAK, p130Cas, p-Shc and p-ERK1/2 in both CNE1-BART1 and 5-8F-BART1 cells. GAPDH was a protein loading
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that the upregulation of BART1 signiﬁcantly reduced the protein
level of PTEN but increased the phosphorylation level of p-Akt,
p-FAK, p130Cas, p-Shc or p-ERK1/2 in either CNE1-BART1 or
5-8F-BART1 cells when compared with the relative control
(Fig. 4a). On the contrary, downregulation of BART1 by in-b1-5p
alone, in-b1-3p alone or both inhibitors increased the PTEN level
but decreased the phosphorylation of p-Akt, p-FAK, p130Cas,
p-Shc or p-ERK1/2 in both CNE1-BART1 and 5-8F-BART1 cells
(Fig. 4b). IHC staining on tumour sections of xenografts and
metastasized organs demonstrated that the upregulation of
BART1 signiﬁcantly reduced the expression of PTEN (see Fig. 3d)
but clearly increased the phosphorylation levels of p-Akt,
p130Cas, p-Shc and p-ERK1/2 in 5-8F-BART1 tumours compared
with the 5-8F-mock tumours (Fig. 4c). Collectively, these results
indicate that EBV-miR-BART1 activates PTEN-dependent
signalling pathways by decreased PTEN in NPC.
EBV-miR-BART1 compels EMT. We investigated the expression
of E-cadherin, N-cadherin and vimentin, as well as the rearran-
gement of actin cytoskeleton, a characteristic event of EMT.
Western blotting demonstrated that the upregulation of BART1
strikingly decreased the expression of E-cadherin but increased
the expressions of N-cadherin and vimentin in both CNE1-
BART1 and 5-8F-BART1 cells compared with the relative control
cells (Fig. 5a). In agreement with the upregulation results,
downregulation of BART1 by in-b1-5p alone, in-b1-3p alone or
both inhibitors increased the E-cadherin expression but decreased
the expression of N-cadherin and vimentin in both CNE1-BART1
and 5-8F-BART1 cells as compared with the in-NC control
(Fig. 5b). IHC staining on tumour sections of xenografts and
metastasized organs demonstrated that the upregulation of
BART1 overtly reduced the E-cadherin expression but increased
the expression of vimentin in 5-8F-BART1 tumours compared
with the 5-8F-mock control tumours (Fig. 5c).
We then performed IF staining for F-actin with Rhodamine-
phalloidin. Confocal microscopy examinations showed that the
upregulation of BART1 modestly increased the expression density
of F-actin and triggered actin cytoskeleton rearrangement in both
CNE1-BART1 and 6-8F-BART1 cells as compared with that of
relative mock control cells. The organization of the actin bundles
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Figure 5 | EBV-miR-BART1 compels EMT. (a) Upregulation of EBV-miR-BART1 expression by retrivirus transductions decreased the protein level
of E-cadherin but increased the expression level of N-cadherin and vimentin in both CNE1-BART1 and 5-8F-BART1 cells. (b) Downregulation of
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enhanced the rearrangement of actin cytoskeleton. Stress ﬁbres and actin ﬁlaments were visualized by Rhodamine-phalloidin staining (red) in NPC cells
tranduced with lentivirus (green for GFP). Nuclei were stained with DAPI (blue). Upregulation of BART1 modestly increased F-actin expression (red)
and actin stress ﬁbres throughout the BART1-expressing cells compared with the control cells in which the actin bundles were predominantly localized
underneath cell membranes. Original magniﬁcation,  1,200; scale bar, 5 mm.
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and associated proteins underneath the cell membranes (that is,
cortical actin cytoskeleton) was clearly observed in either CNE1-
mock or 5-8F-mock cells. In sharply contrast, dynamic structures
of actin ﬁlaments and associated proteins (that is, actin stress
ﬁbre) throughout the cells, characteristic of migrating mesench-
ymal cells45, were explicitly visualized in both CNE1-BART1 and
5-8F-BART1 cells (Fig. 5d). Taken together, the results suggest
that EBV-miR-BART1 promotes cell motility and invasiveness by
driving EMT and increasing actin stress ﬁbres in NPC cells.
Restored PTEN rescues the phenotypes produced by BART1.
We transfected the PTEN expression vector into CNE1-BART1
and 5-8F-BART1 cells. Restitution of PTEN expression
(Supplementary Fig 6) signiﬁcantly reduced the migration
(Fig. 6a) and invasion (Fig. 6b) of both CNE1-BART1 and 5-8F-
BART1 cells compared with the relative PTEN-negative plasmid
control (NC). Detection of the key components of PTEN-
dependent pathways by western blotting demonstrated that the
restoration of PTEN protein decreased phosphorylation levels of
p-Akt, p-FAK, p130Cas, p-Shc and p-ERK1/2 in both CNE1-
BART1 and 5-8F-BART1 cells compared with the relative NC
control (Fig. 6c). In addition, reinstallation of PTEN markedly
increased the expression of E-cadherin but decreased protein
levels of N-cadherin and vimentin in both CNE1-BART1 and
5-8F-BART1 cells compared with the relative NC control
(Fig. 6d). Clearly, the reconstitution of PTEN emulated the results
obtained from the downregulation of EBV-miR-BART1 by in-b1
inhibitors (see Fig. 2c,d, Fig. 4b and Fig. 5b).
Reproducibility of the phenotypes in EBV-positive NPC cells.
We quantiﬁed the expression of EBV-miR-BART1 in three
EBV-positive NPC cell lines (that is, C666-1-EBV, HONE1-EBV
and HK1-EBV) by qRT–PCR. The expression levels of both
BART1-5p and BART1-3p were found comparable among three
EBV-positive cell lines although lower in the cell lines than in
NPC clinical samples (Supplementary Fig. 7a). We used HONE1-
EBV cell line as a representative to validate the function of BART1
in NPC metastasis and underlying molecular mechanisms.
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Figure 6 | Reconstitution of PTEN rescues the phenotypes generated by EBV-miR-BART1. (a) Reconstitution of PTEN reduced the cell migration of both
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Transwell migration and Boyden chamber invasion assays
demonstrated that the downregulation of endogenous BART1 by
either in-b1-5p or in-b1-3b (Supplementary Fig. 7b) signiﬁcantly
decreased the migration (Fig. 7a) and invasion (Fig. 7b) of
HONE1-EBV cells compared with the in-NC control. An additive
effect was obtained when combined the two BART1 inhibitors
(see Fig. 7a,b). Examination of the key components of
PTEN-dependent pathways by western blotting showed that the
downregulation of endogenous BART1 increased PTEN expres-
sion but decreased the phosphorylation of p-Akt, p-FAK and
p-ERK1/2 in HONE1-EBV-positive cells compared with the
in-NC control (Fig. 7c). In agreement with the results obtained
from EBV-negative NPC cell lines (see Fig. 5b), downregulation
of endogenous BART1 increased E-cadherin expression but
decreased the expression of N-cadherin and vimentin in HONE1-
EBV cells compared with the in-NC control (see Fig. 7c). Thus,
the results from the EBV-positive cell line substantiate that
EBV-miR-BART1 promotes cell motility and invasiveness by
activating PTEN-dependent signalling pathway and driving EMT.
Discussion
In this study, we have demonstrated that EBV-miR-BARTs
are highly upregulated while cellular miRNAs are largely
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downregulated in NPC specimens. EBV-miR-BART1, 7, 3, 10, 8,
9, 5, 6, 2, 14 and 16 were all upregulated (Supplementary Table 2),
reminiscent of the pattern of abundance of individual BART
miRNAs in C666-1-EBV-positive cell line, C15 xenograft tumour
and clinical samples of NPC10,15,16,20,24,46, highlighting the
association of latent EBV infection with NPC and the
importance of EBV BART miRNAs in NPC. Surprisingly, more
than half (55.6%) of the downregulated miRNAs are tumour
suppressor miRNAs, including the let-7 family, miR-34 family,
miR-29 family, miR-30 family, miR-26 family, miR-143/145
cluster, miR-16, miR-31, miR-101, miR-146a, miR-150, miR-152
and miR-195, suggesting that effects of EBV infection on NPC
may be partially through regulating the abundance of cellular
tumour suppressive miRNAs. Consistent with our ﬁndings, EBV-
infected AGS cells were shown to decrease the overall abundance
of human miRNAs with speciﬁc downregulation of three types of
tumour suppressive miRNAs, let-7 family, miR-200 family and
miR-143 (refs 5,16).
Several of these upregulated EBV BART miRNAs have been
partially deﬁned in epithelial carcinomas such as BART5 that
inhibited cell apoptosis through targeting PUMA25, BART3* that
promoted cellular growth by targeting DICE1 (ref. 47), BART5,
1-5p, 16 and 17-5p that have been linked to viral latency by
targeting LMP1 (refs 23,48), BART9 that increased tumour
metastasis by targeting E-cadherin49, and BART7-3p that
promoted tumour metastasis by regulation of the PTEN-PI3K/
Akt-EMT pathway50. Here we demonstrated that EBV-miR-
BART1 is closely associated with pathological and clinical stages,
suggesting that BART1 may contribute to NPC metastasis,
underscoring the clinical signiﬁcance. To test this hypothesis, we
modulated the expression of BART1 in both EBV-negative and
EBV-positive NPC cells and revealed that BART1 signiﬁcantly
propels the migration and invasion of NPC cells in vitro and the
tumour metastasis in vivo animal models. Thus, our ﬁndings shed
new lights on the association of EBV BART miRNAs with NPC
metastasis.
To explore underlying mechanisms of EBV-miR-BART1 in
NPC invasion and metastasis, we exploited the integrated strategy
consisting of RNA-deep sequencing, literature retrieval and
pathway enrichment analysis, bioinformatics prediction, lucifer-
ase reporter assay and expression validation of targeted gene in
cell lines, xenograft tumours and clinical samples to investigate
targeted genes and related signalling pathways. We have
identiﬁed 995 downregulated genes and many important path-
ways regulated by BART1. We found that PTEN is the major
cellular target of BART1 in NPC. PTEN, one of the most
frequently mutated and deleted tumour suppressor in the
multitude of tumour types51, has frequently been reported
downregulated in NPC52,53 while the mutation or deletion of
PTEN has rarely been detected in oral squamous cell
carcinoma54, suggesting other mechanisms in NPC are likely
responsible for the downregulation of PTEN. Consistently, we
found that the expression of PTEN is extremely lower (4.4-fold)
in NPC than that of NP and highly inversely correlated with the
expression of BART1-5p or BART1-3p in NPC. More strikingly,
the expression PTEN is decreased by 2.4-fold in advanced clinical
stages III–IV compared with that of early clinical stages I–II,
concomitant with the higher expression of BART1 (3.4-fold for
BART1-5p, 3.0-fold for BART1-3p) in advanced stages III–IV
than that of early stages I–II. Recently, many human miRNAs
including but not limited to miR-26a, 29b, 141, 144, 205 and 221
were reported to target PTEN in various tumours53,55–57.
However, we found that several of these miRNAs including
miR-26a, 29b, 144 and 221 are signiﬁcantly downregulated in
NPC (see Supplementary Table 2), implying that EBV BART
miRNAs in NPC may be more important than cellular miRNAs
in the PTEN dosage regulation. Indeed, BART1 (both BART1-5p
and BART1-3p) and BART7-3p target PTEN in NPC. It was
noted that, based on bioinformatics analysis or PAR-CLIP
predictions, several BART miRNAs (that is, BART9 and
BART18-5p in NPC cells; BART2-5p, BART5, BART14* and
BART21-3p in BC1 or AGS cells) would be possible to regulate
PTEN5,46,58. However, their authenticity in epithelial carcinomas
remains to be determined.
PTEN functions both as a dual speciﬁcity protein phosphatase
and a lipid phosphatase59. The principal catalytic function
of PTEN is to dephosphorylate phosphatidylinositol 3,4,5-
trisphosphate (PIP3), a secondary messenger for Akt, to
phosphatidylinositol 4,5-bisphosphate, thereby suppressing
PI3K-Akt signalling by preventing PIP3-dependent processes
such as the membrane recruitment and the activation of Akt and
PKC. PTEN is also able to dephosphorylate protein substrates
such as FAK and Shc, thus inhibiting the FAK-p130Cas
pathway60. Moreover, PTEN is capable of regulating MAPK–
ERK1/2 signalling either by dephosphorylating Shc (resulting in
the inactivation of Ras, Raf and ultimately ERK1/2) or by
reducing PIP3-mediated activation of PKC and Akt (leading to
the suppression of Raf, MEK and ERK1/2)61. In NPC, we found
that BART1 signiﬁcantly increased the phosphorylation levels of
p-Akt, p-FAK, p130Cas, p-Shc and p-ERK1/2 in NPC cell lines.
Importantly, such expression alterations also occurred in vivo, as
revealed by IHC staining on tumour sections of xenografts and
metastasized organs. Therefore, we concluded that EBV-miR-
BART1 impels the migration and metastasis by targeting cellular
PTEN and consequently activating PI3K-Akt, FAK-p130Cas and
MAPK–ERK1/2 pathways in NPC.
EMT, a fundamental biological process that enables polarized
epithelial cells to convert mesenchymal-like cells, which includes
the rearrangement of actin cytoskeleton and enhanced migratory
and invasive capacity, is considered as the initial step of tumour
metastasis62. FAK/p130Cas, PI3K/Akt and MAPK/ERK pathways
were known to regulate EMT and promote cell migration45,62. In
this study, we demonstrated that EBV-miR-BART1 in NPC cells
signiﬁcantly reduced the expression of E-cadherin, an important
caretaker for the epithelial phenotype, but increased the
expression of N-cadherin and vimentin, two goalkeepers for the
mesenchymal phenotype. Consistently, downregulation of EBV-
miR-BART1 increased the expression of E-cadherin but
decreased the expression of N-cadherin and vimentin in NPC
cell lines. IHC staining on tumour sections of xenografts and
matastasized organs conﬁrmed that BART1 decreased the
expression of E-cadherin but increased the expression of
vimentin in vivo. In clinical tumour samples, the expression of
E-cadherin was reported downregulated and inversely correlated
with lymph node metastasis of NPC63. Interestingly, we also
found that BART1 modestly increased F-actin level and triggered
actin cytoskeleton rearrangement in NPC cells apparently by
activating FAK-p130Cas and Shc-MEK-ERK1/2 pathways59–61.
Collectively, our ﬁndings indicated that EBV-miR-BART1
increases cell motility and invasiveness by impelling EMT and
increasing actin stress ﬁbres in NPC cells.
In conclusion, we have demonstrated that EBV-miR-BART1 is
highly expressed in NPC and closely associated with advanced
stages of the patients. BART1 increased the cell migration and
invasion of NPC in vitro and impelled the tumour metastasis
in vivo by directly targeting PTEN. Reduction of PTEN dosage by
BART1 activated PTEN-dependent pathways, compelled EMT
and consequently increased the migration, invasion and metas-
tasis of NPC (Fig. 7d). Reconstitution of PTEN expression
rescued all phenotypes generated by BART1, highlighting the
dominant role of PTEN in EBV-miR-BART-driven metastasis in
NPC. Our ﬁndings provide new insights into the invasiveness and
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metastasis of NPC regulated by EBV and rational for the
development of clinical intervention strategies for NPC.
Methods
Cell culture. Two EBV-negative NPC cell lines (CNE1 and 5-8F)64,65 and
HEK293T cells were obtained from Cancer Research Institute Southern Medical
University. Three EBV-positive NPC cell lines (HONE1-EBV, HK1-EBV and
C666-1-EBV) were kindly provided by Professor S.-W. Tsao, University of Hong
Kong. The NPC cell lines were cultured in RPMI-1640 (Invitrogen) supplemented
with 10% newborn cow serum (NCS; Hyclone, Invitrogen), 100Uml 1 penicillin
and 100mgml 1 streptomycin, while HEK293T cells grew in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen) with 10% NCS, 100Uml 1 penicillin and
100mgml 1 streptomycin. All cells were maintained at 37 C with 5% CO2.
Patients and clinical tissue specimens. Primary NPC (no treatment before
biopsy taking) and NP biopsies were collected from patients in Zhongshan People’s
Hospital, Guangdong, China. Informed written consent was obtained from all
subjects and approval from the Ethics Committee of Zhongshan People’s Hospital
was obtained for research purposes in use of clinical materials. Twenty NPC and
20 NP specimens were used for microarray analysis and qRT–PCR validation
(Supplementary Table 1) and another cohort containing 82 NPC specimens with
TNM staging and 32 NP specimens were collected for the association analysis of
EBV-miR-BART1 expression with pathological and clinical data (Supplementary
Table 3). Only those NPC samples that contain 480% of homogeneous cancer
cells on frozen cross-sections visualized by haematoxylin–eosin staining were
included in this study. Staging was performed according to the China 1992 Fuzhou
NPC staging system.
qRT–PCR. Total RNA was extracted with TRIzol reagent (Invitrogen),
complementary DNA (cDNA) was synthesized with the PrimeScript RT reagent
Kit (TaKaRa, Dalian, China). qRT–PCR was performed in triplicate with SYBR
Premix ExTaq (TaKaRa, Dalian, China). The primers used for ampliﬁcation of the
interested genes were listed in Supplementary Table 5. Quantiﬁcation of EBV-miR-
BART1 was conducted with TaqMan microRNA assays (Applied Biosystems).
Mature miRNAs were reverse transcribed, and qRT–PCR was performed using
All-in-One miRNA qRT–PCR Detection Kit following the manufacturer’s protocol
(GeneCopoeia). RPU6B and GAPDH were used for normalizing the expression of
miRNA and mRNA, respectively. The fold changes were calculated by using the
2DDCt method.
MiRNA microarray analysis. MiRNA microarrays (CCDTM-miRNA850-V4p1.4)
were kindly provided by Infectious Disease and Immunogenetics section,
Department of Transfusion Medicine, Clinical Center, National Institutes of
Health, USA. Total RNA was labelled by miRCURY LNA miRNA Power Labeling
Kit (Exiqon Life Sciences, Vedbaek, Denmark) according to the manufacturer’s
instruction. The test sample and the reference were labelled with Hy5 and Hy3,
respectively, and co-hybridized to the miRNA arrays. The hybridized arrays were
scanned by LuxScanTM 10K microarray Scanner (Capital Bio. Corporation,
Beijing, China). The resulting data ﬁles were uploaded to the mAdb database. Any
gene containing one of the follows was excluded: (1)o20% of expression data had
at least a 1.5-fold-change in either direction from gene’s median value; (2) per cent
of data missing of ﬁltered out exceeds 50%. Further analysis was done by using the
BRB-Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). Expression
proﬁle clustering and visualization were preformed with Cluster and Treeview
software (Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA,
USA). The raw data were deposited in GEO database (Superseries Accession
Number: GSE42945).
Lentivirus transductions. Lentiviral particles containing the GV209 expression
vector encoding 282-nt pri-EBV-miR-BART1 precursor that produces both
BART1-5p and BART1-3p (H1-miRNA-CMV-EGFP-BART1) and randomized
ﬂanking sequence control (H1-miRNA-CMV-EGFP-mock; Supplementary Fig. 8)
were purchased from GeneChem (Shanghai, China) and transduced into NPC cells
following the manufacturer’s instructions. The virus-infected cells, being GFP
positive, were sorted out by BD FACS Aria cell sorter after 72 h.
Plasmid preparation and cell transfection. The expression vector GV230 (http://
www.genechem.com.cn) containing whole coding sequence of PTEN and the
control vector GV170 were purchased from GeneChem (Shanghai, China). Plasmid
DNAs were puriﬁed with TIANprep Mini Plasmid Kit (TIANGEN, China). Both
CNE1-BART1 and 5-8F-BART1 cells were transfected with 200 ng plasmid DNA
using Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours post transfection,
the cells were harvested for qRT–PCR and western blotting analyses. miRNA
mimics or inhibitors (miRNA antisense oligonucleotides) were transfected at
50 nmol l 1 with Lipofectamine 2000 reagent (Invitrogen). The EBV-miR-BART1-
5p mimic (50-UCUUAGUGGAAGUGACGUGCUGUG-30), EBV-miR-BART1-3p
mimic (50-UAGCACCGCUAUCCACUAUGUC-30), EBV-miR-BART1-5p
inhibitor (50-CACAGCACGUCACUUCCACUAAGA-30), EBV-miR-BART1-3p
inhibitor (50-GACAUAGUGGAUAGCGGUGCUA-30) and associated nonspeciﬁc
mimic (50-UUGUACUACACAAAAGUACUG-30) or inhibitor (50-CAGUACUU
UUGUGUAGUACAA-30) controls were synthesized by GenePharma, Shanghai,
China.
Transwell migration and Boyden chamber invasion assays. For the transwell
migration assay, 105 cells in 100 ml of serum-free DMEM media were triplicate
seeded in each ﬁbronectin-coated polycarbonate membrane insert in a transwell
apparatus (Corning). 600ml of 10% NCS in DMEM was added to the bottom
chamber. CNE1 and 5-8F cells were incubated at 37 C for 18 h and 12 h,
respectively. The inserts were washed twice with prewarmed PBS. Cells adhered on
the lower surface were ﬁxed with 100% methanol at RT for 15min and stained with
hematoxylin for 15min. Cell numbers in six predetermined ﬁelds in each replicate
were counted under the microscope (NiKon ECLPSE 80i system;  200). All assays
were independently repeated at least for three times. Cell invasion assays were
performed as the migration assay except the transwell membrane was precoated
with 24mgml 1 Matrigel (R&D Systems) and the cells were incubated for 24 and
18 h, respectively.
Western blotting. Western blotting analyses were performed by using standard
methods. In brief, cells were harvested and lysed in the RIPA buffer containing
protease inhibitors (Sigma-Aldrich) and phosphatase inhibitors (Keygen, China).
Proteins were separated by SDS–polyacrylamide gel electrophoresis gels, and
blotted onto PVDF membrane (Millipore). The membrane was probed with the
ﬁrst antibody listed in Supplementary Table 6 and then with the peroxidase-
conjugated secondary antibody. GAPDH was used as a protein loading control.
Western blotting bands were visualized by eECL Western Blot Kit (CWBIO
Technology) and captured with ChemiDocTM CRSþ Molecular Imager
(Bio-Rad). All blots in ﬁgures were accompanied by the locations of molecular
weight/size markers. Original blotting images for the key components of
PTEN-dependent pathways and EMT were shown in Supplementary Fig. 9.
Tumour xenografts in nude mice. Animal experiments were approved by the
Ethical Committee for Animal Research of Southern Medical University (protocol
number: 2011-020) and conducted based on the state guidelines from the Ministry
of Science and Technology of China. All nude mice (4–5 weeks old, female) were
purchased from the Central Animal Facility of Southern Medical University. To
assess tumour growth, 200 ml of 5-8F-BART1 cells or mock control cells (107) was
subcutaneously injected into the left or right side on the back of each mouse (seven
mice per group). The tumour sizes were measured regularly and calculated using
the formula¼ 0.52 LW2 where L and W are the long and short diameter of the
tumour, respectively.
We chose the well-established mouse model to evaluate tumour metastasis43,44.
Under the anaesthesia by peritoneal injection of 1% pentobarbital sodium, a small
cut on the abdominal region was made. The mouse liver was gently pushed out of
abdominal cavity and 50 ml of 5-8F cells (2 106) was then injected underneath the
liver envelope. The liver was then pushed back into abdominal cavity after lightly
pressed the pinhole with alcohol cotton balls for two minutes. All mice (seven per
group) were killed on day 21 after transplantation, or earlier if the mouse reached
the ethical endpoint. Whole bodies, freshly dissected tumours and internal organs
including lungs, livers and lymph nodes were collected for ﬂuorescence imaging
with the LT-9MACIMSYSPLUS whole-body imaging system (Encinitas, CA)29.
Tumour tissues were ﬁxed in 4% paraformaldehyde for 48 h and transferred to
gradient ethanol. Tumours were embedded in parafﬁn, sectioned with LeiCa
RM2235 and processed for histological examinations.
F-actin staining and confocal microscope examinations. F-actin staining was
monitored by Rhodamine-phalloidin (5mgml 1) and 40 ,6-diamidino-2-pheny-
lindole (DAPI) (0.1 mgml 1) staining according to the manufacturer’s instruc-
tions. In brief, the cells were seeded on sterile coverslips with monolayer on the day
before staining. Cells were then washed with prewarmed PBS twice, ﬁxed with 4%
paraformaldehyde in PBS for 10min and washed with PBS three times, each for
5min. Cells were then permeablized with cold 100% acetone for 5min, washed and
treated with 1% bovine serum albumin/PBS/0.1% azide for 30min for blocking
nonspeciﬁc binding. Subsequently, cells were stained with Rhodamine-phalloidin at
RT for 30min, washed with PBS twice, stained for nuclei with DAPI for 1min. The
coverslips were mounted on slides using anti-fade mounting medium. Confocal
images were acquired on the OLYMPUS confocal micrograph system, and analysed
with FV10-ASW1.7 viewer software (Olympus).
IF assays. Cells were cultured on coverslips overnight, ﬁxed with 4% formaldehyde
in PBS for 15min at 4 C and then permeabilized with 0.5% Triton-X-100 in PBS
for 30min. Subsequently, cells were blocked for nonspeciﬁc binding with 5% milk
in TBS and Tween-20 (TBST) at RT for 30min, incubated with PTEN-speciﬁc
antibody (1:100, Bioworld) at 4 C overnight. The cells were incubated with Alexa
Fluor 488 goat anti-rabbit IgG (1:500, Sigma-Aldrich) at 37 C for 1 h. The
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coverslips were mounted on slides using anti-fade mounting medium with DAPI.
IF images were acquired on Nikon ECLIPSE 80i microscope (Nikon).
IHC staining. Parafﬁn sections prepared from in vivo experiments were applied to
IHC staining for the detection of protein levels of PTEN and some key components
of PTEN-pathways. The indirect streptavidin-peroxidase method was used29. All
antibodies used for IHC were listed in Supplementary Table 6. The stained results
were reviewed and scored by two pathologists independently 66. In brief, the
intensity of immunostaining was scored as negative (0), weak (1), medium (2) and
strong (3). The extent of staining, deﬁned as the per cent of positive staining cells,
was scored as 1 (r10%), 2 (11–50%), 3 (51–75%) and 4 (475%). An overall
expression score, ranging from 0 to 12, was obtained by multiplying the score of
intensity and that of extent. The ﬁnal staining score was presented as negative
(overall score of (0), 1þ (overall score of 1–3), 2þ (overall score of 4) or 3þ
(overall score of Z5).
RNA-deep sequencing. RNA-deep sequencing was performed and analysed in
BGI-Shenzhen of China. In brief, mRNAs were isolated from the DNase-treated
total RNAs with the Dynabeads mRNA Puriﬁcation Kit (Life Technologies).
According to the manufacturer’s instructions, the mRNAs were fragmented with
divalent cations and converted to single-strand cDNA with random hexamer
primers and Superscript II reverse transcriptase (Life Technologies). The second
strand of cDNA was generated by RNase H (Enzymatics) and DNA polymerase.
cDNA products were puriﬁed by Ampure beads XP (Beckman). After converting
the overhangs into blunt ends using T4 DNA polymerase and Klenow DNA
polymerase, extra ‘A’ base was added to the 30-end of cDNA by Klenow enzyme.
Sequencing adapters were then ligated to the end of cDNA by T4 DNA Ligase
(Enzymatics). The fragments of 200 bp were selected by Ampure beads XP
(Beckman) and enriched by 12 cycles of PCR. The PCR products were loaded into
ﬂowcell to generate clusters and then sequenced by Hiseq 2000 (Illumina). The
resulting data were deposited in GEO database (Accession Number: GSE42945).
Selected results were shown in Supplementary Table 4.
MiRNA target predictions. EBV-miR-BART1 candidate targets were initially
obtained from the RNA-deep sequencing in BGI-Shenzhen of China
(Supplementary Table 4) and then enriched with literature retrieval. The RNA-
hybrid programme (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.
html) was used to predict duplex complementation between human PTEN 30-UTR
and EBV-miR-BART1-5p or EBV-miR-BART1-3p.
Luciferase reporter assays. The MiTarget microRNA 30-UTR target vector
(pEZX-MT01) containing full-length 30-UTR of PTEN with two binding sites for
EBV-miR-BART1-5p and EBV-miR-BART1-3p (wild-type 30-UTR) was produced
by GeneCopoeia. Two mutant sites (mut1 and mut2) in PTEN 30-UTR were then
generated by site-directed mutagenesis with KOD-Plus-Mutagenesis Kit (SMK-101,
Toyobo C. Ltd). For luciferase reporter assays, wt or mut 30-UTR vector was
co-transfected with EBV-miR-BART1 mimic or nonspeciﬁc mimic control
(Genepharma) into HEK 293T cells, respectively. Luciferase activity was measured
48 h after transfection using Luc-Pair miR Luciferase Assay Kit (GeneCopoeia) on
Panomics Luminometer.
Statistical analysis. All experiments were performed in triplicate. Data shown
are mean±s.e.m. (unless otherwise speciﬁed) from at least three independent
experiments. SPSS 16.0 software was used for statistical analyses. Differences were
considered to be statistically signiﬁcant at values of Po0.05 by Student’s t-test for
two groups, one-way ANOVA (analysis of variance) analysis for multiple groups
and parametric generalized linear model with random effects for tumour growth.
Correlation was analysed with two-tailed Spearman’s correlation analysis. Single,
double and triple asterisks indicate statistical signiﬁcance—*Po0.05, **Po0.01
and ***Po0.001.
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Supplementary	  Figure	  1.	  Up-­‐regulation	  of	  EBV-­‐miR-­‐BART1	   in	  both	  CNE1	  and	  5-­‐8F	  cells	  by	  
lentivirus-­‐mediated	  transduction	  
Lentiviral	  particles	  carrying	  282-­‐nt	  pri-­‐EBV-­‐miR-­‐BART1	  precursor	  (H1-­‐miRNA-­‐CMV-­‐GFP-­‐BART1)	  
or	  a	  BART1	  control	  sequence	  (H1-­‐miRNA-­‐CMV-­‐GFP-­‐mock)	  was	  transduced	  into	  EBV-­‐negative	  
NPC	  cell	  lines.	  QRT-­‐PCR	  confirmed	  the	  up-­‐regulation	  of	  EBV-­‐miR-­‐BART1	  in	  either	  CNE1-­‐BART1	  
(a)	  or	  5-­‐8F-­‐BART1	  (b)	  cells	  compared	  with	  relative	  mock	  control	  cells.	  The	  expression	  level	  of	  
EBV-­‐miR-­‐BART1	  in	  either	  CNE1-­‐BART1	  or	  5-­‐8F-­‐BART1	  cells	  was	  very	  close	  to	  the	  mean	  level	  of	  
20	  NPC	  specimens	  (P>0.05)	  that	  used	  for	  the	  miRNA-­‐microarray	  profile	  analysis.	  Student’s	  t	  
test,	  mean	  ±	  SEM,	  N=3,	  ***P<0.001.	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Supplementary	  Figure	  2.	  Wound-­‐healing	  assays	  evaluating	  the	  migration	  of	  NPC	  cells	   	  
Up-­‐regulation	   of	   EBV-­‐miR-­‐BART1	   increased	   the	   migration	   of	   both	   CNE1-­‐BART1	   and	  
5-­‐8F-­‐BART1	  cells	  compared	  with	  that	  of	  CNE1-­‐mock	  and	  5-­‐8F-­‐mock	  control	  cells	  respectively.	  
Wound-­‐healing	  pictures	  were	  taken	  at	  0,	  6,	  12,	  and	  24hr	  after	  scratch.	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Supplementary	   Figure	   3.	   Down-­‐regulation	   of	   the	   expression	   of	   EBV-­‐miR-­‐BART1	   in	   both	  
CNE1-­‐BART1	  and	  5-­‐8F-­‐BART1	  cells	  by	  transfection	  of	  BART1-­‐inhibitory	  oligonucleotide	  
Either	   CNE1-­‐BART1	   cells	   (a)	   or	   5-­‐8F-­‐BART1	   cells	   (b)	   was	   transfected	   with	   the	  
BART1-­‐inhibitory	   oligonucleotide	   (in-­‐b1-­‐5p	   for	   the	  BART1-­‐5p	   inhibitor	   and	   in-­‐b1-­‐3p	   for	   the	  
BART1-­‐3p	   inhibitor)	   or	   the	   non-­‐specific	   inhibitor	   control	   (in-­‐NC)	   at	   50nM	   by	   using	  
Lipofectamine	   2000	   reagent.	   The	   expression	  of	   BART1	   (either	   BART1-­‐5p	  or	   BART1-­‐3p)	  was	  
determined	   by	   qRT-­‐PCR.	   Either	   in-­‐b1-­‐5p	   or	   in-­‐b1-­‐3p	   specifically	   down-­‐regulated	   the	  
expression	  of	  BART1-­‐5p	  or	  BART1-­‐3p	  respectively.	  The	  combination	  of	  in-­‐b1-­‐5p	  and	  in-­‐b1-­‐3p	  
down-­‐regulated	   both	   BART1-­‐5p	   and	   BART1-­‐3p.	   Student’s	   t	   test,	   mean	   ±	   SEM,	   N=3,	  
***P<0.001.	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Supplementary	   Figure	   4.	   Validation	   of	   EBV-­‐miR-­‐BART1	   expression	   in	   liver-­‐metastasized	  
tumors	  of	  mice	  xenografted	  with	  5-­‐8F	  NPC	  cells	   	  
QRT-­‐PCR	   confirmed	   the	   up-­‐regulation	   of	   BART1	   (either	   BART1-­‐5p	   or	   BART1-­‐3p)	   in	  
liver-­‐metastasized	   tumors	   of	  mice	   implanted	  with	   5-­‐8F-­‐BART1	   cells	   compared	  with	   that	   of	  
5-­‐8F-­‐Mock	   control.	   The	   expression	   level	   of	   either	   BART1-­‐5p	   or	   BART1-­‐3p	   in	  
liver-­‐metastasized	   tumors	  was	   very	   close	   to	   the	  mean	   level	   of	   20	  NPC	   specimens	   (P>0.05)	  
that	   used	   for	   the	   miRNA-­‐microarray	   profile	   analysis.	   Student’s	   t	   test,	   mean	   ±	   SEM,	   N=3,	  
***P<0.001.	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Supplementary	   Figure	   5.	   Putative	   migration/metastasis-­‐associated	   candidate	   genes	  
enriched	   from	   those	   EBV-­‐miR-­‐BART1	   down-­‐regulated	   genes	   obtained	   from	   RNA-­‐deep	  
sequencing	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Supplementary	  Figure	  6.	  Reconstitution	  of	  PTEN	  expression	  in	  CNE1-­‐BART1	  and	  5-­‐8F-­‐BART1	  
cells	  validated	  by	  qRT-­‐PCR	  
The	   expression	   vector	   GV230	   containing	   whole	   coding	   sequence	   of	   PTEN	   and	   the	   control	  
vector	   GV170	   (200ng)	   were	   transfected	   into	   CNE1-­‐BART1	   and	   5-­‐8F-­‐BART1	   cells	   by	   using	  
Lipofectamine	  2000	  reagent.	  After	  48hr,	  total	  RNAs	  were	  extracted	  from	  the	  transfected	  cells.	  
QRT-­‐PCR	   confirmed	   the	   restoration	  of	   PTEN	  at	  mRNA	   level.	   Student’s	   t	   test,	  mean	  ±	   SEM,	  
N=3,	  ***P<0.001.	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Supplementary	  Figure	  7.	  Basal	  expression	  of	  EBV-­‐miR-­‐BART1	  in	  three	  EBV-­‐positive	  NPC	  cell	  
lines	  and	  down-­‐regulation	  of	  endogenous	  BART1	  expression	  in	  HONE1-­‐EBV	  cells	  
(a)	  Expression	  of	  BART1	  (either	  BART1-­‐5p	  or	  BART1-­‐3p)	  in	  three	  EBV-­‐positive	  cell	  lines	  and	  20	  
NPC	  clinical	  samples	  as	  quantified	  by	  qRT-­‐PCR.	   	  
(b)	   Expression	  of	  BART1	   (either	  BART1-­‐5p	  or	  BART1-­‐3p)	  was	   significantly	  decreased	  by	   the	  
BART1	   inhibitory	   oligonucleotides	   (in-­‐b1-­‐5p,	   in-­‐b1-­‐3p	   or	   both)	   but	   not	   by	   the	   control	  
oligonucleotide	  (in-­‐NC).	  Mean	  ±	  SEM,	  N=3,	  ***P<	  0.001.	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Supplementary	  Figure	  8.	  Construction	  and	  sequence	  validation	  of	  the	  lentiviral	  expression	  
vector	  used	  for	  up-­‐regulation	  of	  EBV-­‐miR-­‐BART1	   	  
(a)	   The	   GV209	   lentiviral	   vector	   (H1-­‐miRNA-­‐CMV-­‐EGFP-­‐BART1)	   containing	   282-­‐nt	   of	  
pri-­‐EBV-­‐miR-­‐BART1	   precursor.	   The	   BART1-­‐5p	   and	   BART1-­‐3p	   sequences	   are	   underlined	   by	  
blue	  and	  green	  color	  respectively.	  AgeI	  (ACCGGT)	  and	  EcoRI	  (GAATTC)	  restriction	  sites	  of	  the	  
insert	  are	  capitalized	  in	  red	  color.	  
(b)	  Sequence	  validation	  of	  EBV-­‐miR-­‐BART1	  by	  sequencing	  the	  insert.	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Supplementary	   Figure	   9.	   Original	   Western	   blotting	   images	   of	   the	   key	   components	   of	  
PTEN-­‐dependent	  pathway	  and	  EMT	  
	  Supplementary	  Tables	  
	  
Supplementary Table 1. A cohort of clinical tissue samples for miRNA-microarray 
analysis and qRT-PCR validation (*Independent t test; §Chi-square test. SCC, 
squamous cell carcinoma) 
Characteristics 
           Clinical tissue samples 
NP (n=20) NPC (n=20) P-value 
Age 40.10 43.35 0.45* 
Gender, male 9 (45%) 14 (70%) 0.11§ 
Poorly differentiated SCC  3 (15%)  
Undifferentiated cancer  17 (85%)  
Differentiated SCC  0  
	  Supplementary Table 2. Identification of 69 miRNAs that are differentially expressed between 
NPC and NP 
ID of miRNA  
Fold-change  
(NPC/NP) 
Parametric 
P-value* 
FDR 
Permutation 
P-value 
Geom mean of 
ratios in NP 
Geom mean of 
ratios in NPC 
EBV-mir-BART1 19.27250161 < 1e-07 < 1e-07 < 1e-07 0.8125691 15.660236 
EBV-mir-BART7 18.07791945 < 1e-07 < 1e-07 < 1e-07 0.9346132 16.8958559 
EBV-mir-BART3 17.58748896 < 1e-07 < 1e-07 < 1e-07 0.9132633 16.0620225 
EBv-miR-BART10 14.69989431 < 1e-07 < 1e-07 < 1e-07 1.1458645 16.8440805 
EBV-mir-BART8 9.488377212 < 1e-07 < 1e-07 < 1e-07 1.1705958 11.1070561 
EBV-mir-BART9 8.929823198 < 1e-07 < 1e-07 < 1e-07 1.0091342 9.0113889 
EBV-mir-BART5 7.846405052 < 1e-07 < 1e-07 < 1e-07 0.9187861 7.2091699 
EBV-mir-BART6 7.118709463 1.00E-07 7.40E-06 < 1e-07 0.7954561 5.6626205 
EBV-miR-BART2 6.916700789 < 1e-07 < 1e-07 < 1e-07 1.3506757 9.3422202 
EBV-mir-BART14 4.411855538 3.00E-07 1.92E-05 < 1e-07 1.2572036 5.5466018 
EBV-mir-BART16 3.987080265 2.50E-06 0.0001412 < 1e-07 1.0048799 4.0065376 
hcmv-miR-UL22A-1 3.885736046 < 1e-07 < 1e-07 < 1e-07 0.7876988 3.0607896 
EBV-mir-BART4 3.787084074 7.00E-07 4.20E-05 < 1e-07 0.9391749 3.5567349 
hsa-mir-643 3.265885184 0.0004774 0.0100596 4.00E-04 0.7455299 2.4348153 
hsa-miR-205 3.248118933 6.92E-05 0.002076 3.00E-04 6.728439 21.8547711 
hsa-mir-660 3.147664166 0.0002148 0.0054265 7.00E-04 1.6899949 5.3195365 
hsa-mir-651 2.851257861 5.44E-05 0.0018651 4.00E-04 0.8795513 2.5078271 
EBV-mir-BART12 2.823659898 2.38E-05 0.000952 < 1e-07 0.8353809 2.3588313 
hsa-mir-613 2.792151931 5.84E-05 0.0019264 3.00E-04 0.7482905 2.0893406 
hsa-mir-581 2.696646908 0.00028 0.0064 8.00E-04 1.0545058 2.8436301 
EBV-mir-BART17 2.290131754 0.0025353 0.0325018 0.0043 1.2044927 2.7584471 
EBV-mir-BART20 1.963470804 0.001917 0.0259484 0.002 1.0313375 2.025001 
hcmv-miR-US25-2-5p 1.751267173 0.0004925 0.0100596 5.00E-04 0.7969985 1.3957573 
hsa-mir-604 1.707947764 0.0002276 0.0055488 3.00E-04 0.8396544 1.4340858 
hsa-miR-191 0.675653489 0.0024665 0.0324362 0.0012 1.2266716 0.8288049 
hsa-miR-199a 0.667823292 0.0016459 0.0232362 0.001 1.0138932 0.6771015 
hsa-let-7i 0.624801665 0.0032592 0.0391692 5.00E-04 1.6666703 1.0413384 
hsa-miR-26a 0.583824466 0.002897 0.0361184 0.0014 3.2261411 1.8835 
hsa-let-7c 0.573459207 0.0009439 0.0158973 5.00E-04 0.9209456 0.5281247 
hsa-miR-221 0.563403611 0.0019191 0.0259484 0.0022 0.956716 0.5390172 
hsa-let-7d 0.562094115 0.0014468 0.021702 0.0012 0.9135164 0.5134822 
hsa-miR-375 0.553670369 0.0028318 0.0357701 0.0026 1.056692 0.585059 
hsa-miR-136 0.55210868 0.0013857 0.0211154 0.0016 1.8847563 1.0405903 
hsa-miR-10b 0.548276244 0.0007865 0.014246 0.0012 0.5592348 0.3066151 
hsa-miR-199b 0.536033283 0.001025 0.0169655 0.0017 1.8175629 0.9742742 
hsa-miR-30a-5p 0.520525329 2.35E-05 0.000952 < 1e-07 4.7382753 2.4663923 
hsa-miR-30d 0.520322198 0.0002312 0.0055488 < 1e-07 4.3641825 2.2707811 
hsa-miR-152 0.51214102 0.0005287 0.010574 6.00E-04 2.6944112 1.3799185 
hsa-miR-145 0.500895953 0.0043537 0.0491712 0.0062 17.6262937 8.8289392 
	  Notes: 
Normalization: Normalize (center) each array using lowess smoother.  
Exclude a gene under any of the following conditions: <20% of expression data have ≥1.5-fold change in either 
direction from gene's median value. Percent of data missing or filtered out exceeds 50%. 
*Global test: probability of getting at least 69 genes significant by chance (at the 0.005 level). 
FDR, False discovery rate.  
Tumor suppressor miRNAs are highlighted with colors. 
	  
	  
	  
	  
	  
hsa-mir-624 0.48726506 0.0032641 0.0391692 0.0032 1.3162108 0.6413435 
hsa-miR-365 0.485030362 0.0016908 0.0235242 0.0028 0.8250951 0.4001962 
hsa-let-7g 0.480341011 0.0004898 0.0100596 < 1e-07 1.7995287 0.8643874 
hsa-miR-31 0.477838587 0.0006132 0.0115426 6.00E-04 0.4731818 0.2261045 
hsa-miR-199a* 0.473994909 0.0036812 0.0425777 0.0051 2.6174524 1.2406591 
hsa-miR-196b 0.471017271 0.003782 0.0432229 0.0063 1.5101803 0.711321 
hsa-miR-30e-5p 0.458486626 2.80E-06 0.0001493 < 1e-07 6.0942278 2.7941219 
hsa-miR-195 0.447332403 0.0008874 0.0154892 0.0015 1.99611 0.8929247 
hsa-miR-29a 0.437574812 2.33E-05 0.000952 < 1e-07 4.1010735 1.7945265 
hsa-miR-16 0.435157393 0.0045243 0.0505038 0.0051 1.8793853 0.8178284 
hsa-miR-29b 0.431569238 0.0001835 0.0047611 1.00E-04 1.7628566 0.7607947 
hsa-miR-346 0.42473145 0.0005502 0.0107794 0.0016 4.9578175 2.1057411 
hsa-miR-146a 0.418978959 2.77E-05 0.0010228 < 1e-07 10.756221 4.5066303 
hsa-miR-30b 0.406976952 0.0003932 0.0085789 2.00E-04 4.5581951 1.8550803 
hsa-miR-342 0.397489125 2.77E-05 0.0010228 < 1e-07 8.6870346 3.4530018 
hsa-miR-449 0.396329922 0.0035867 0.0419906 0.0079 6.6484496 2.6349795 
hsa-miR-143 0.379372457 0.000574 0.0110208 8.00E-04 43.9659697 16.6794781 
hsa-miR-144 0.37808031 0.0006346 0.0117157 0.0014 47.9652601 18.1347207 
hsa-miR-29c 0.36916765 8.40E-06 0.0004244 < 1e-07 4.5125747 1.6658966 
hsa-miR-126* 0.362801182 0.000942 0.0158973 0.0028 9.3399427 3.3885423 
hsa-miR-140 0.331890429 0.0008268 0.0146987 0.0017 2.2027896 0.7310848 
hsa-miR-30a-3p 0.322618985 2.15E-05 0.000952 < 1e-07 4.5292535 1.4612231 
hsa-miR-485-3p 0.317850375 0.0011268 0.0180288 0.0021 13.4029323 4.2601271 
hsa-miR-26b 0.312392088 4.29E-05 0.0015253 < 1e-07 4.4792998 1.3992978 
hsa-miR-105 0.304738919 0.0001367 0.0037495 6.00E-04 2.615638 0.7970867 
hsa-miR-32 0.282737728 0.0021969 0.029292 0.0049 2.6416395 0.7468911 
hsa-miR-101 0.26323514 8.98E-05 0.0025355 3.00E-04 2.5906225 0.6819429 
hsa-miR-150 0.253107259 6.02E-05 0.0019264 3.00E-04 20.454355 5.1771457 
hsa-miR-34b 0.173349588 3.00E-07 1.92E-05 < 1e-07 3.0396284 0.5269183 
hsa-miR-34c 0.126005664 < 1e-07 < 1e-07 < 1e-07 1.614109 0.2033869 
	   
Supplementary Table 3. A cohort of clinical samples used for the association 
analysis with pathological and clinical data 
  Clinical tissue samples  
 NP (n=32)   NPC (n=82)    P-value 
Age, years 43.18  54.65   0.076* 
Gender, male     18 (65.63%)    54 (65.85%)  0.390§ 
T stage    
T1     18 (21.95%)  
T2  22 (26.83%)  
T3  20 (24.39%)  
T4  22 (26.83%)  
N stage    
N0   7 (8.54%)  
N1  26 (31.71%)  
N2  33 (40.24%)  
N3  16 (19.51%)  
M stage    
   M0   77 (93.90%)  
   M1   5 (6.10%)  
M2   0  
M3   0  
TNM stage    
I  15 (18.29%)  
II  22 (26.83%)  
III  25 (30.49%)  
IV  20 (24.39%)  
*Independent t test. §Chi-square test. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  
Supplementary Table 4. Candidate genes and their associated pathways 
Gene symbol Fold-change  P-value   Pathways* 
PTEN  0.422484  8.35E-18 5 
NRAS  0.470386  6.71E-23 2 
CHUK  0.411017  1.31E-07 3 
SOS2  0.495144  7.63E-11 3 
CYCS  0.415773  1.51E-51 3 
BAX  0.433427  0.000129 1 
TNFRSF10D 0.257243  1.05E-06 1 
CDK1  0.33074  8.87E-09 1 
ROCK1  0.408148  6.83E-13 1 
ATR  0.34964  4.08E-23 1 
SERPINB5  0.418178  4.31E-35 1 
HSP90AA1  0.081898  5.94E-32 2 
BIRC3  0.227606  3.61E-05 3 
BIRC2  0.234874  1.05E-23 3 
MGST2  0.260917  1.02E-27 2 
EGLN3  0.26978  2.00E-28 1 
MSH2  0.336967  6.10E-26 1 
CUL2  0.403895  4.71E-08 1 
SP100  0.372665  2.11E-06 1 
TPR  0.446203  1.88E-40 1 
CCNA2  0.457381  9.58E-28 1 
MYLK3  0.220494  1.84E-06 1 
PPP1CC  0.462373  9.43E-79 1 
*Metastasis/invasion-associated pathways in which candidate genes were involved. 
These pathways are p53 signaling pathway, pathway in cancer, prostate cancer, 
focal adhesion and small cell lung cancer. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  Supplementary Table 5. Primer sequences 
Gene Primer Sequence 
PTEN Forward 5'-TGCAGAAGAAGCCCCGCCA-3' 
 Reverse 5'-ACGCCTTCAAGTCTTTCTGCAGG-3' 
mut1* Forward 5'-AACGCAAGGTTTCCGAAGGGTTTTGC-3' 
 Reverse 5'-CAACTGCAAACTTATCTGTTGCCAC-3' 
mut2§ Forward 5'-CGAAGAAAATTCAGATGCTGTTAG-3' 
 Reverse 5'-TGGCCTTGATTACACTGGAGATGG-3' 
GAPDH Forward 5'-GCCACATCGCTCAGACACCA-3' 
 Reverse 5'-CTCAGCCTTGACGGTGCCAT-3' 
*Mut1, PTEN 3’-UTR containing mutant EBV-miR-BART1-5p binding site; 
§Mut2, PTEN 3’-UTR containing mutant EBV-miR-BART1-3p binding site  
	  
Supplementary Table 6. A list of antibodies used for Western blotting and IHC staining  
Name of antibody Cat. No Company Mol weight Dilution (WB/IHC) 
PTEN (D375) pAb BS1305 Bioworld 54kDa 1:800/1:200 
FAK phospho (pY576) 2103-1 Epitomics 125kDa 1:5000 
Anti-FAK antibody BM0503 ABZOOM 119kDa 1:1000 
Anti-ERK1/2 antibody BM0431 ABZOOM 43kDa 1:1000 
pErk1 (pT202)/Erk2 (pT185)  1481-1 Epitomics 42/44kDa 1:3000/1:100 
p-Shc (Tyr239/240) 2434 CST 52kDa 1:800/1:200 
p-Paxillin (Y31) pAb BS4721 Bioworld 68kDa 1:800 
H/K/N-Ras (H27) pAb BS1309 Bioworld 25kDa 1:800/1:200 
p130Cas (v404) pAb BS1416 Bioworld 130kDa 1:800/1:200 
Anti-AKT (p-Ser473) AM1006 ABZOOM 60kDa 1:1000/1:200 
E-cadherin (24E10) mAb 3195 CST 135kDa 1:500/1:100 
N-Cadherin (C-term) 2019-1 Epitomics 140kDa 1:1000 
Vimentin 
GAPDH 
BS1776 
P30008 
Bioworld 
Abmart 
57kDa 
37kDa 
1:500/1:100 
1:1000 
